Fulcrum Therapeutics reported net income of -$26.23M for the quarter ended Jun 2026. This income statement covers 33 quarters of results from Jun 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 40.53M | 40.63M | 40.68M | 41.01M | 52.05M | 52.10M | 61.76M | 52.10M | 52.10M | 61.92M | 62.14M | 62.25M | 53.94M | 53.97M | 53.98M | 54.09M | 54.11M | 66.58M | 66.61M | 76.29M | |||||||||||||
| Revenue & cost | |||||||||||||||||||||||||||||||||
| Revenue | 4.93M | 5.06M | 2.59M | 1.88M | 1.18M | 0.69M | 0.29M | 0.88M | 0.76M | 0.87M | 80.00M | ||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 17.08M | 18.91M | 17.83M | 25.02M | 15.37M | 18.57M | 16.71M | 17.85M | 18.24M | 19.00M | 19.77M | 17.26M | 14.64M | 11.71M | 13.40M | 12.99M | 14.30M | 15.42M | 14.08M | 12.44M | |||||||||||||
| Selling, General & AdministrativeSG&A | 8.63M | 9.71M | 10.76M | 11.10M | 9.71M | 10.13M | 11.52M | 10.32M | 9.96M | 9.86M | 10.06M | 10.25M | 8.42M | 7.72M | 7.00M | 6.83M | 7.56M | 7.28M | 8.10M | 7.46M | |||||||||||||
| Restructuring CostsRestructuring | 0.47M | -0.04M | 2.06M | 4.32M | |||||||||||||||||||||||||||||
| Other Operating ExpensesOther Opex | 5.09M | ||||||||||||||||||||||||||||||||
| Operating ExpensesOpex | 25.70M | 28.62M | 28.59M | 36.12M | 25.54M | 28.66M | 28.23M | 28.17M | 28.20M | 28.86M | 29.83M | 27.51M | 25.13M | 19.43M | 20.40M | 19.82M | 21.86M | 22.69M | 22.19M | 29.31M | |||||||||||||
| Operating IncomeOp. Inc | -20.77M | -23.56M | -26.00M | -34.23M | -24.36M | -27.97M | -27.94M | -27.29M | -27.44M | -27.99M | -29.83M | 52.49M | -25.13M | -19.43M | -20.40M | -19.82M | -21.86M | -22.69M | -22.19M | -29.31M | |||||||||||||
| EBIT | -20.77M | -23.56M | -26.00M | -34.23M | -24.36M | -27.97M | -27.94M | -27.29M | -27.44M | -27.99M | -29.83M | 52.49M | -25.13M | -19.43M | -20.40M | -19.82M | -21.86M | -22.69M | -22.19M | -29.31M | |||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.05M | -0.53M | -0.69M | 0.02M | 0.62M | 1.84M | 0.15M | -0.55M | 3.42M | 3.24M | -0.30M | 0.07M | 3.43M | 2.86M | -0.06M | 2.52M | 2.26M | 2.36M | -0.69M | 3.13M | |||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | |||||||||||||||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||
| EBT | -20.72M | -24.09M | -26.69M | -34.21M | -23.74M | -26.14M | -27.79M | -27.84M | -24.02M | -24.76M | -30.13M | 52.56M | -21.70M | -16.57M | -20.46M | -17.30M | -19.59M | -20.33M | -22.87M | -26.18M | |||||||||||||
| Profit After TaxPAT | -20.72M | -23.88M | -25.93M | -34.07M | -23.74M | -26.54M | -24.78M | -23.78M | -24.02M | -24.76M | -26.87M | 55.41M | -21.70M | -17.08M | -17.66M | -17.30M | -19.59M | -20.33M | -18.89M | -26.23M | |||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -20.72M | -24.09M | -26.69M | -34.21M | -23.74M | -26.14M | -27.79M | -27.84M | -24.02M | -24.76M | -30.13M | 52.56M | -21.70M | -16.57M | -20.46M | -17.30M | -19.59M | -20.33M | -22.87M | -26.18M | |||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -20.72M | -24.09M | -26.69M | -34.21M | -23.74M | -26.14M | -27.79M | -27.84M | -24.02M | -24.76M | -30.13M | 52.56M | -21.70M | -16.57M | -20.46M | -17.30M | -19.59M | -20.33M | -22.87M | -26.18M | |||||||||||||
| Income towards Parent CompanyParent Net Inc | -20.72M | -24.09M | -26.69M | -34.21M | -23.74M | -26.14M | -27.79M | -23.78M | -24.02M | -24.76M | -30.13M | 55.41M | -21.70M | -16.57M | -20.46M | -17.30M | -19.59M | -20.33M | -22.87M | -26.18M | |||||||||||||
| Preferred Dividend PaymentsPref Dividends | |||||||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -20.72M | -24.09M | -26.69M | -34.21M | -23.74M | -26.14M | -27.79M | -23.78M | -24.02M | -24.76M | -30.13M | 55.41M | -21.70M | -16.57M | -20.46M | -17.30M | -19.59M | -20.33M | -22.87M | -26.18M | |||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||
| EPS (Basic) | -0.57 | -0.68 | -0.66 | -0.84 | -0.51 | -0.58 | -0.47 | -0.38 | -0.39 | -0.40 | -0.49 | 0.89 | -0.35 | -0.27 | -0.33 | -0.28 | -0.31 | -0.32 | -0.30 | -0.34 | |||||||||||||
| EPS (Diluted) | -0.57 | -0.68 | -0.66 | -0.84 | -0.51 | -0.58 | -0.47 | -0.38 | -0.39 | -0.40 | -0.49 | 0.87 | -0.35 | -0.27 | -0.33 | -0.28 | -0.31 | -0.32 | -0.30 | -0.34 | |||||||||||||
| Shares Outstanding | 36.61M | 35.36M | 40.64M | 40.89M | 46.21M | 44.99M | 59.72M | 61.79M | 61.82M | 61.31M | 61.98M | 62.20M | 62.41M | 61.98M | 62.48M | 62.54M | 62.60M | 63.35M | 76.22M | 76.26M | |||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 36.61M | 35.36M | 40.64M | 40.89M | 46.21M | 44.99M | 59.72M | 61.79M | 61.82M | 61.31M | 61.98M | 63.59M | 62.41M | 61.98M | 62.48M | 62.54M | 62.60M | 63.35M | 76.22M | 76.26M | |||||||||||||
| EBITDA | -20.77M | -23.56M | -26.00M | -34.23M | -24.36M | -27.97M | -27.94M | -27.29M | -27.44M | -27.99M | -29.83M | 52.49M | -25.13M | -19.43M | -20.40M | -19.82M | -21.86M | -22.69M | -22.19M | -29.31M |